GAITHERSBURG, Md., Nov. 4, 2015 /PRNewswire/ -- GenVec, Inc. (NASDAQ: GNVC), a clinical-stage gene delivery company, announced that Douglas E. Brough, Ph.D., the company's chief scientific officer, has given a presentation entitled "Gorilla Adenovirus Vectors for Molecular Therapeutics and Vaccines" at the Vaccines R&D-2015 Conference in Baltimore taking place November 2-4. The presentation highlighted the differentiated and superior performance characteristics seen with GenVec's gorilla adenovectors for molecular vaccines, which have been shown to generate strong, durable antibody and T cell responses to an encoded antigen after a single administration.
Most recently, GenVec has combined its gorilla adenovectors with novel malaria antigens and protein vaccine approaches developed by Patrick E. Duffy, M.D. and colleagues at the Laboratory of Malaria Immunology and Vaccinology (LMIV). LMIV is part of the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health. The experimental vaccine combination produced promising results in preclinical models designed to test vaccine candidates that are designed to block transmission of malaria parasites by carrier mosquitoes.
"These preclinical data generated by our collaborators show high levels of durable antibody responses to LMIV's antigens. These antibodies can be taken up by a mosquito when it bites a vaccinated individual and stop oocyst generation, neutralizing the parasite and blocking further transmission," said Dr. Brough.
The slides from Dr. Brough's presentation are available online in the Presentations listing under Investors & Media at www.genvec.com.
GenVec is a clinical-stage gene delivery company focused on developing a pipeline of cutting-edge therapeutics and vaccines using its proprietary AdenoVerse™ platform. The company is a pioneer in the design, testing and manufacture of adenoviral-based product candidates that can deliver on the promise of gene-based medicine. GenVec's lead product candidate, CGF166, is licensed to Novartis and is currently in a Phase 1/2 clinical study for the treatment of hearing loss and balance disorders. In addition to its internal and partnered pipeline, the company is also focused on opportunities to license its proprietary technology platform, including vectors and production cell lines, for the development and manufacture of therapeutics and vaccines to the biopharmaceutical industry. Additional information about GenVec is available at www.genvec.com and in the company's various filings with the Securities and Exchange Commission.
Statements herein relating to future financial or business performance, conditions or strategies and other financial and business matters, including with respect to GenVec's hearing loss and balance disorders program are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. GenVec cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, such as the failure of Novartis to advance GenVec's hearing loss and balance disorders program. Further information on the factors and risks that could affect GenVec's business, financial conditions and results of operations, are contained in GenVec's filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. These forward-looking statements speak only as of the date of this press release, and GenVec assumes no duty to update forward-looking statements.
Dian Griesel Int'l.
Media: Susan Forman
Investors: Cheryl Schneider
Telephone: (212) 825-3210
SOURCE GenVec, Inc.